Arvinas, Inc (ARVN)

Price$7.42

Value ScoreB

Growth ScoreD

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-48.99%

Price vs S&P 500 (4W)-26.60%

VGM Score41.58

Market Capitalization$478.75M

All Metrics

Book Value / Share (Quarterly)$6.00

P/TBV (Annual)2.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)25.96%

Cash Flow / Share (Quarterly)$-3.98

Price vs S&P 500 (YTD)-45.59%

Net Profit Margin (TTM)-247.54%

EPS (TTM)$-3.26

10-Day Avg Trading Volume0.74M

EPS Excl Extra (TTM)$-3.26

Revenue Growth (5Y)64.50%

EPS (Annual)$-1.14

ROI (Annual)-18.60%

Net Profit Margin (5Y Avg)-239.63%

Cash / Share (Quarterly)$9.53

Revenue Growth QoQ (YoY)-91.74%

ROA (Last FY)-11.26%

Revenue Growth TTM (YoY)-79.06%

EBITD / Share (TTM)$-3.65

ROE (5Y Avg)-36.82%

Operating Margin (TTM)-283.78%

Cash Flow / Share (Annual)$-4.34

P/B Ratio1.24x

P/B Ratio (Quarterly)1.75x

Net Income / Employee (Annual)$-328,500

EV / Revenue (TTM)4.38x

Net Interest Coverage (TTM)-2.48x

ROA (TTM)-28.38%

EPS Incl Extra (Annual)$-1.14

Current Ratio (Annual)4.92x

Quick Ratio (Quarterly)5.36x

3-Month Avg Trading Volume0.87M

52-Week Price Return7.23%

Revenue / Employee (TTM)$363,400

Tangible BV / Share (Quarterly)$8.31

P/S Ratio (Annual)1.82x

Asset Turnover (Annual)0.37x

52-Week High$14.51

Operating Margin (5Y Avg)-254.02%

EPS Excl Extra (Annual)$-1.14

CapEx CAGR (5Y)-21.56%

Tangible BV CAGR (5Y)370.17%

26-Week Price Return-41.06%

Quick Ratio (Annual)4.85x

13-Week Price Return-45.92%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.44x

Enterprise Value$391.75M

Revenue / Share Growth (5Y)46.34%

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-12.40%

Revenue / Employee (Annual)$1,067,500

Pretax Margin (Annual)-30.65%

Cash / Share (Annual)$10.79

3-Month Return Std Dev52.44%

Net Income / Employee (TTM)$-899,600

ROE (Last FY)-18.62%

EPS Basic Excl Extra (Annual)$-1.14

P/FCF (TTM)9.61x

Receivables Turnover (TTM)81.27x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.26

Receivables Turnover (Annual)78.39x

ROI (TTM)-44.35%

P/S Ratio (TTM)5.36x

Pretax Margin (5Y Avg)-233.90%

Revenue / Share (Annual)$3.70

Tangible BV / Share (Annual)$10.62

Price vs S&P 500 (52W)-17.14%

Year-to-Date Return-37.44%

5-Day Price Return-13.52%

EPS Normalized (Annual)$-1.14

ROA (5Y Avg)-18.40%

Net Profit Margin (Annual)-30.77%

Month-to-Date Return-17.37%

Cash Flow / Share (TTM)$-5.17

EBITD / Share (Annual)$-1.63

Operating Margin (Annual)-45.13%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-36.77%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.26

P/TBV (Quarterly)2.63x

P/B Ratio (Annual)1.76x

Pretax Margin (TTM)-247.20%

Book Value / Share (Annual)$6.83

Price vs S&P 500 (13W)-54.17%

Beta1.73x

P/FCF (Annual)0.86x

Revenue / Share (TTM)$1.40

ROE (TTM)-44.38%

52-Week Low$6.06

vGradeB

gGradeD

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.90est. -0.94

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.81

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ARVNArvinas, Inc	B	D	D	$7.42
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapies using its proprietary PROTAC platform, which harnesses the body's natural protein disposal system. The company is advancing a pipeline of clinical-stage candidates in oncology and neurology, including ARV-102, ARV-806, vepdegestrant, and others. The PROTAC approach offers a potentially differentiated mechanism for selectively eliminating disease-causing proteins.